309 related articles for article (PubMed ID: 20425438)
1. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.
Osterborg A; Karlsson C; Lundin J
Curr Hematol Malig Rep; 2009 Jan; 4(1):47-53. PubMed ID: 20425438
[TBL] [Abstract][Full Text] [Related]
2. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).
Karlsson C; Hansson L; Celsing F; Lundin J
Leukemia; 2007 Mar; 21(3):511-4. PubMed ID: 17215854
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia.
Lundin J; Karlsson C; Celsing F
Med Oncol; 2006; 23(1):137-9. PubMed ID: 16645240
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia?
D'Arena G; Taylor RP; Cascavilla N; Lindorfer MA
Endocr Metab Immune Disord Drug Targets; 2008 Mar; 8(1):62-8. PubMed ID: 18393924
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab.
Cheung WW; Hwang GY; Tse E; Kwong YL
Haematologica; 2006 May; 91(5 Suppl):ECR13. PubMed ID: 16709521
[TBL] [Abstract][Full Text] [Related]
6. Treatment of severe autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab.
Royer B; Vaida I; Etienne A; Garidi R; Damaj G; Marolleau JP
Leukemia; 2007 Aug; 21(8):1841-2; author reply 1842-3. PubMed ID: 17460703
[No Abstract] [Full Text] [Related]
7. Monoclonal antibodies in the treatment of chronic lymphocytic leukemia.
Liu NS; O'Brien S
Med Oncol; 2004; 21(4):297-304. PubMed ID: 15579912
[TBL] [Abstract][Full Text] [Related]
8. Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia.
Rossignol J; Michallet AS; Oberic L; Picard M; Garon A; Willekens C; Dulery R; Leleu X; Cazin B; Ysebaert L
Leukemia; 2011 Mar; 25(3):473-8. PubMed ID: 21127498
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune cytopenias in chronic lymphocytic leukemia.
D'Arena G; Guariglia R; La Rocca F; Trino S; Condelli V; De Martino L; De Feo V; Musto P
Clin Dev Immunol; 2013; 2013():730131. PubMed ID: 23690826
[TBL] [Abstract][Full Text] [Related]
10. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab.
Zent CS; Secreto CR; LaPlant BR; Bone ND; Call TG; Shanafelt TD; Jelinek DF; Tschumper RC; Kay NE
Leuk Res; 2008 Dec; 32(12):1849-56. PubMed ID: 18584865
[TBL] [Abstract][Full Text] [Related]
11. A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia.
Kaufman M; Limaye SA; Driscoll N; Johnson C; Caramanica A; Lebowicz Y; Patel D; Kohn N; Rai K
Leuk Lymphoma; 2009 Jun; 50(6):892-9. PubMed ID: 19391041
[TBL] [Abstract][Full Text] [Related]
12. A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia.
Tsang M; Parikh SA
Curr Hematol Malig Rep; 2017 Feb; 12(1):29-38. PubMed ID: 28197963
[TBL] [Abstract][Full Text] [Related]
13. Evolving role of monoclonal antibodies in the treatment of chronic lymphocytic leukemia.
Kharfan-Dabaja MA; Fahed R; Hussein M; Santos ES
Expert Opin Investig Drugs; 2007 Nov; 16(11):1799-815. PubMed ID: 17970639
[TBL] [Abstract][Full Text] [Related]
14. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia.
Gupta N; Kavuru S; Patel D; Janson D; Driscoll N; Ahmed S; Rai KR
Leukemia; 2002 Oct; 16(10):2092-5. PubMed ID: 12357362
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases.
Zaja F; Vianelli N; Sperotto A; Patriarca F; Tani M; Marin L; Tiribelli M; Candoni A; Baccarani M; Fanin R
Leuk Lymphoma; 2003 Nov; 44(11):1951-5. PubMed ID: 14738149
[TBL] [Abstract][Full Text] [Related]
16. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias.
Gómez-Almaguer D; Solano-Genesta M; Tarín-Arzaga L; Herrera-Garza JL; Cantú-Rodríguez OG; Gutiérrez-Aguirre CH; Jaime-Pérez JC
Blood; 2010 Dec; 116(23):4783-5. PubMed ID: 20841509
[TBL] [Abstract][Full Text] [Related]
17. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.
D'Arena G; Laurenti L; Capalbo S; D'Arco AM; De Filippi R; Marcacci G; Di Renzo N; Storti S; Califano C; Vigliotti ML; Tarnani M; Ferrara F; Pinto A
Am J Hematol; 2006 Aug; 81(8):598-602. PubMed ID: 16823816
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia.
Laurenti L; Tarnani M; Efremov DG; Chiusolo P; De Padua L; Sica S; Leone G
Leukemia; 2007 Aug; 21(8):1819-21; author reply 1821. PubMed ID: 17443222
[No Abstract] [Full Text] [Related]
19. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.
Jaglowski SM; Alinari L; Lapalombella R; Muthusamy N; Byrd JC
Blood; 2010 Nov; 116(19):3705-14. PubMed ID: 20610811
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab for B-cell chronic lymphocytic leukemia.
Robak T
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1033-51. PubMed ID: 18588450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
